ABBV vs DXCM
By Alex · Tickerpine
AbbVie Inc. vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | DXCM |
|---|---|---|
| Price | $285.64 | $77.94 |
| Market cap | $504.76B | $29.41B |
| P/E ratio | 80.5 | 30.9 |
| ROE | — | 38.49% |
| Profit margin | 9.80% | 20.12% |
| Revenue growth | 10.20% | 13.10% |
| Dividend yield | 2.42% | 0.00% |
| Beta | 0.23 | 1.48 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs DXCM in plain English
- ABBV is the bigger company — about 17.2× the market cap of DXCM.
- DXCM is cheaper on earnings (P/E 30.9 vs 80.5).
- DXCM is growing revenue faster (13% vs 10%).
- ABBV pays a dividend (2.42%) while the other effectively doesn't.
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.